• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

CurieAI Launches AI-Driven Platform for COVID-19 Respiratory Monitoring and Management

by Jasmine Pennic 08/18/2020 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
CurieAI Launches AI-Driven Platform for COVID-19 Respiratory Monitoring and Management

What You Should Know:

– SRI Ventures spin-off CurieAI announces the launch of its AI-driven COVID-19 case management platform

– The Curie solution has been deployed to monitor inpatients and outpatients at San Carlos Apache Healthcare Corporation (SCAHC).


CurieAI, a Menlo Park, CA-based healthcare startup spun-off from SRI Ventures, the corporate venture arm of SRI International, today announced the release of CurieAI’s first-of-its-kind AI-driven platform specifically designed for assisting in the monitoring and management of respiratory conditions surrounding COVID-19. Early deployments indicate that Curie’s solution could prove invaluable in managing COVID-19 positive patients.  

In the latest deployment for COVID-19, the Curie solution has been adopted to monitor inpatients and outpatients at San Carlos Apache Healthcare Corporation (SCAHC). The facility currently serves a population of 20,000 on a reservation in Peridot, Arizona.  

How It Works

Curie’s system continuously monitors the breathing patterns and gives a daily objective assessment of the level of respiratory distress the patient is experiencing. The assessment is personalized to each patient and provided to the physicians with actionable insights on the disease state severity, condition progression, and early detection of any deterioration in the condition. 

“We have seen direct correlation with Curie to be able to predict if a patient is improving or having more severe symptoms,” said Dr. James Darragh, Chief Medical Officer at SCAHC. “The first patient I specifically recollect was a patient who had already been treated with Remdesivir and dexamethasone. We saw the Curie monitor turn into a red or warning level and we repeated a chest x-ray and saw that it was significantly worse. This discovery led to our successful use of the COVID convalescent plasma with subsequent recovery of the patient which may have not been possible without Curie monitoring the patient.” 

With COVID-19 treatment options in limited supply, early detection of deterioration becomes critical while deciding next steps. Curie’s solution has been shown to be critical in identifying both deterioration as well as identifying stable or improving patients. 

Milestones to Date

Since the beginning of the pandemic, Curie has monitored close to 300 COVID-19 patients. With the existing and new deployments, Curie is expanding the offering to assist in the monitoring and management of up to 3,000 COVID-19 patients by the end of the year.  

A key differentiating component of CurieAI’s platform is its unique patient monitoring for enabling early detection of exacerbations achieved with technology detection of respiratory health biomarkers through monitoring of the patient’s breathing patterns, captured with standard audio sensors.  

The information from the daily objective assessment, combined with a secure HIPAA compliant platform, enables proactive interventions to improve patient outcomes while preventing adverse events like emergency room visits and hospitalizations. Curie’s solution has shown strong outcomes in patient populations with chronic respiratory conditions; an early pilot on moderate to severe asthma population showed a 90% reduction in ER visits and hospitalizations.  

“Actionable data on the disease progression and an early detection of the deterioration in the condition plays an extremely important role in the treatment of respiratory conditions,” said Navya Davuluri, Co-Founder and CEO of Curie. “And with our proprietary technology for respiratory health assessment we enable exactly that and help clinicians make proactive interventions.” 

Availability

CurieAI’s platform has been live for commercial deployments since early 2020 and is used actively by physicians in better managing a variety of respiratory conditions including COPD, Asthma, Fibrosis and more.  

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: AI, Artificial Intelligence, Asthma, Biomarkers, Case Management, COPD, Coronavirus (COVID-19), HIPAA, Patient Monitoring, physicians, sensors

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Kinetik CEO Sufian Chowdhury on Fighting NEMT Fraud & Waste

Most-Read

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

'Cranky Index' Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

‘Cranky Index’ Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

Madison Dearborn Partners to Acquire Significant Stake in NextGen Healthcare

Madison Dearborn Partners to Acquire Significant Stake in NextGen Healthcare

Wandercraft Begins Clinical Trials for Physical AI-Powered Personal Exoskeleton

Wandercraft Begins Clinical Trials for Physical AI-Powered Personal Exoskeleton

Chipiron Secures $17M to Transform MRI Access with Portable Scanner

Chipiron Secures $17M to Transform MRI Access with Portable Scanner

Abbott to Integrate FreeStyle Libre Glucose Data with Epic EHR

Abbott to Integrate FreeStyle Libre Glucose Data with Epic EHR

5 Ways New Trump Administration Tariffs Are Impacting U.S. Healthcare Now

5 Ways Trump Administration Tariffs Are Impacting U.S. Healthcare Now

iCAD, GE HealthCare Integrate to Advance Breast Cancer Detection with AI

RadNet to Acquire iCAD for $103M in All-Stock Transaction

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |